Loading company
Loading
Latest annual · FY2025
Millions- Total revenues
- 2,870
- Gross profit
- 2,228
- Operating income
- (1,405)
- Net income
- (1,136)
- Free cash flow
- 281
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- -45.1%
- Revenue, 5 yearsFY2020 to FY2025
- +42.9%
- Net income, 5 yearsFY2020 to FY2025
- n/m
BioNTech SE (BNTX) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | €2.9 billion | €2.8 billion | +4.3% | 20-F 2026-03-10 · proof |
| Gross profit | €2.2 billion | €2.2 billion | +0.8% | 20-F 2026-03-10 · proof |
| Operating income | -€1.4 billion | -€1.3 billion | 20-F 2026-03-10 · proof | |
| Net income | -€1.1 billion | -€665.3 million | 20-F 2026-03-10 · proof | |
| Cash from operating activities | €456 million | €207.7 million | +119.5% | 20-F 2026-03-10 · proof |
| Free cash flow | €280.9 million | -€78.8 million | 20-F 2026-03-10 · proof | |
| Total assets | €22 billion | €22.5 billion | -2.4% | 20-F 2026-03-10 · proof |
| Total liabilities | €2.8 billion | €3.1 billion | -11.4% | 20-F 2026-03-10 · proof |
| Cash and cash equivalents | €7.7 billion | €9.8 billion | -21.4% | 20-F 2026-03-10 · proof |
- What was BioNTech SE (BNTX)'s revenue in fiscal 2025?
- BioNTech SE (BNTX) reported revenue of €2.9 billion for fiscal 2025 (the year ended Dec 31, 2025), against €2.8 billion the year before (+4.3%). Source: the 20-F filed with the SEC on Mar 10, 2026. SEC
- What was BioNTech SE (BNTX)'s gross profit in fiscal 2025?
- BioNTech SE (BNTX) reported gross profit of €2.2 billion for fiscal 2025 (the year ended Dec 31, 2025), against €2.2 billion the year before (+0.8%). Source: the 20-F filed with the SEC on Mar 10, 2026. SEC
- What was BioNTech SE (BNTX)'s operating income in fiscal 2025?
- BioNTech SE (BNTX) reported operating income of -€1.4 billion for fiscal 2025 (the year ended Dec 31, 2025), against -€1.3 billion the year before. Source: the 20-F filed with the SEC on Mar 10, 2026. SEC
- What was BioNTech SE (BNTX)'s net income in fiscal 2025?
- BioNTech SE (BNTX) reported net income of -€1.1 billion for fiscal 2025 (the year ended Dec 31, 2025), against -€665.3 million the year before. Source: the 20-F filed with the SEC on Mar 10, 2026. SEC
- What was BioNTech SE (BNTX)'s cash from operating activities in fiscal 2025?
- BioNTech SE (BNTX) reported cash from operating activities of €456 million for fiscal 2025 (the year ended Dec 31, 2025), against €207.7 million the year before (+119.5%). Source: the 20-F filed with the SEC on Mar 10, 2026. SEC
- What was BioNTech SE (BNTX)'s free cash flow in fiscal 2025?
- BioNTech SE (BNTX) reported free cash flow of €280.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -€78.8 million the year before. Source: the 20-F filed with the SEC on Mar 10, 2026. SEC
- What are BioNTech SE (BNTX)'s total assets?
- As of Dec 31, 2025, BioNTech SE (BNTX) reported total assets of €22 billion, against €22.5 billion a year earlier (-2.4%). Source: the 20-F filed with the SEC on Mar 10, 2026. SEC
- What are BioNTech SE (BNTX)'s total liabilities?
- As of Dec 31, 2025, BioNTech SE (BNTX) reported total liabilities of €2.8 billion, against €3.1 billion a year earlier (-11.4%). Source: the 20-F filed with the SEC on Mar 10, 2026. SEC
- What are BioNTech SE (BNTX)'s cash and cash equivalents?
- As of Dec 31, 2025, BioNTech SE (BNTX) reported cash and cash equivalents of €7.7 billion, against €9.8 billion a year earlier (-21.4%). Source: the 20-F filed with the SEC on Mar 10, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:BNTX&period_type=annual&limit=5"Information only, not investment advice.